Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
Reisa A. Sperling(Harvard University), Gary Romano(Janssen (United States)), Johannes Streffer(University of Antwerp), Panna Sanga(Janssen (United States)), Yingqi Shi(Janssen (United States)), John Thipphawong(Janssen (United States)), Michael S. Rafii(University of Southern California), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Paul Aisen(University of California, San Diego), Gerald Novak(Janssen (United States)), Hany Rofael(Janssen (United States)), Rema Raman(University of Southern California), Hartmuth C. Kolb(Johnson & Johnson (United States)), Karin Ernström(University of Southern California), Jennifer Bogert(Janssen (United States)), David Henley(Janssen (United States)), Ziad S. Saad(Janssen (United States)), Nandini Raghavan(Janssen (United States)), Yevgen Tymofyeyev(Janssen (United States)), Keith Karcher(Janssen (United States)), H. Robert Brashear(Brigham and Women's Hospital)
Cited by 110
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k